Roche announces positive studies of MabThera with subcutaneous injection
Roche has reported results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (SC), potentially allowing patients to spend less time in infusion centres receiving their MabThera treatment ...
Trial of 5-Minute Subcutaneous Rituximab Injection: Positive ResultsProHealth
Injectable MabThera® cuts administration time to five minutesPharmacy Europe

all 6 news articles »